<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862615</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0048</org_study_id>
    <secondary_id>IDRCB 2008-A00593-52</secondary_id>
    <secondary_id>AU750</secondary_id>
    <nct_id>NCT00862615</nct_id>
  </id_info>
  <brief_title>Relationships Between Quality of Ageing and Age-related Degenerated Disease (Compalimage)</brief_title>
  <acronym>Compalimage</acronym>
  <official_title>Chronic Micro-inflammation and Bone and Muscular Status in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche en Nutrition Humaine d'Auvergne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      This project aims to assess the impact of chronic micro-inflammation on age-related loss of&#xD;
      muscle (sarcopenia) and bone (osteopenia). The hypothesis is that chronic micro-inflammation&#xD;
      and oxidative stress, which prevalence increases during ageing, may participate in the&#xD;
      pathogenesis of both sarcopenia and osteopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to explore the effect of a moderate chronic inflammation on skeletal muscle function&#xD;
      and protein metabolism and on bone status, two groups of 16 subjects each will be selected&#xD;
      according to their inflammatory status ie non-inflamed versus micro-inflamed. The volunteers&#xD;
      will be sampled twice at week 0 and week 6 in order to quantify plasma concentration of C&#xD;
      reactive protein (CRP) using the ultra sensitive assay. The subjects exhibiting CRP lower&#xD;
      than 1 mg/l twice will be included in the non-inflamed group and the subjects exhibiting CRP&#xD;
      higher than 3 and lower than 15 mg/l will be included in the micro-inflamed group.&#xD;
&#xD;
      During the two weeks before the metabolic studies dietary intakes, DEXA, muscle function, VO2&#xD;
      max and biomarkers of bone remodelling will be assessed. Volunteers will then be submitted to&#xD;
      a diet controlled for its protein content, for 4 days (1 g protein/kg/day and 30 kcal/kg/day)&#xD;
      before metabolic investigations. One day before, urine will be collected for metabolomics. On&#xD;
      the day of metabolic investigations, after an overnight fast, blood samples will be collected&#xD;
      for albumin, fibrinogen, inflammatory cytokine and adipokine determination. Then, the&#xD;
      subjects will be perfused with L-[1-13C] leucine for 8 hours (post absorptive sate then post&#xD;
      prandial satte) during which expired gas and blood samples will be taken, as well as 2 muscle&#xD;
      biopsies. Isotopic enrichments in expired gas, in plasma cetoiscaproate and in free or&#xD;
      protein-bound leucine in muscle will be measured to determine proteolysis and proteosynthesis&#xD;
      rate of muscle proteins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Isotopic enrichments in expired gas, in plasma cetoisocaproate and in free or protein-bound leucine in muscle will be measured to determine proteolysis and proteosynthesis rate of muscle proteins.</measure>
    <time_frame>at week 0 and week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Splanchnic extraction of amino acids, bone metabolism, muscular strength, global metabolism and quality of life.</measure>
    <time_frame>at week 0 and week 6</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Age-related Degenerated Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.</intervention_name>
    <description>Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.&#xD;
Isotopes are :&#xD;
(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Body mass index 21 BMI 30 kg/m2&#xD;
&#xD;
          -  Affiliated to National Health Insurance&#xD;
&#xD;
          -  Subject giving his written informed consent&#xD;
&#xD;
          -  Subject considered as normal after clinical examination and medical questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive serologies to HIV or HCV, determined on blood samples&#xD;
&#xD;
          -  Previous medical and/or surgery judged by the investigator as incompatible with this&#xD;
             study&#xD;
&#xD;
          -  Chronic pathologies : Diabetes, cardiovascular diseases, cancer, chronic inflammation&#xD;
             diseases, renal, pulmonary impairments Reported xylocaïne allergy&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Prostate hypertrophy&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Heavy consumer of alcohol&#xD;
&#xD;
          -  Practising intensive physical exercise&#xD;
&#xD;
          -  Being under someone's supervision&#xD;
&#xD;
          -  Refusal to be registered on the National Volunteers Data file&#xD;
&#xD;
          -  Dietary habits unreliable to controlled food intake&#xD;
&#xD;
          -  Being in exclusion on the National Volunteers Data file&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noël CANO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Dardevet</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Recherche Agronomique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Lacarin</last_name>
    <phone>04.73.75.11.95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lacarin</last_name>
      <phone>04.73.75.11.95</phone>
      <email>placarin@chu-clermont-ferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>September 28, 2010</last_update_submitted>
  <last_update_submitted_qc>September 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Noël CANO</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Ageing</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Muscle protein synthesis</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>Sarcopenia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

